In a sector note on U.S. Medical Supplies and Devices, UBS analyst Danielle Antalffy initiated coverage of Edwards Lifesciences with a Neutral rating and $84 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Wells downgrades Edwards Lifesciences with Medtronic gaining share
- Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
- Bernstein medical tech/devices analysts hold analyst/industry conference call
- Edwards Lifesciences downgraded to Market Perform from Outperform at Raymond James
- Edwards Lifesciences downgraded to Market Perform at Raymond James